Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on share repurchase activity.
- Shares Purchased: 350,000 ordinary shares of 25 pence each.
- Purchase Price: 1,432.9643 pence per share.
- Treasury Shares Held: 198,491,678 shares (post-transaction).
- Shares in Issue: 5,787,816,933 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through a buyback executed on October 2, 2006. This transaction was conducted under authority granted by shareholders at the Annual General Meeting on May 17, 2006. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Points
- Verify the total cost of the 350,000 share repurchase based on the stated price of 1,432.9643 pence.
- Confirm the updated total share count and the proportion of shares held in Treasury.
- Review the original shareholder authorization from the May 17, 2006 Annual General Meeting to ensure the buyback volume remains within approved limits.